
ImageneBio, Inc.
80
Recent developments include merger completion, leadership appointment, capital raising, and strategic restructuring.
- ImageneBio appointed Kristin Yarema, Ph.D., as CEO following the merger of Ikena Oncology and Inmagene Biopharmaceuticals [N3].
- The company completed a 1-for-12 reverse stock split concurrent with the merger announcement and began trading under ticker IMA on Nasdaq [N4].
- ISS and Glass Lewis supported the share issuance for the proposed merger, facilitating shareholder approval [N5][N6].
- A definitive merger agreement was announced on December 23, 2024, to advance development of IMG-007 [N7][N8].
- ImageneBio unveiled a $30 million private placement to advance IMG-007 development [N1].
- Ikena Oncology trading resumed on December 23, 2024, coinciding with merger activities [N7].
- The company announced strategic restructuring and exploration options in May 2024 [N14].
ImageneBio, Inc. operates in the biopharmaceutical sector, formed by the merger of Ikena Oncology and Inmagene Biopharmaceuticals. The company focuses on developing IMG-007, a drug candidate in its pipeline. The merger involved a reverse stock split and was supported by major proxy advisory firms ISS and Glass Lewis. Leadership changes include the appointment of Kristin Yarema, Ph.D., as CEO. The company has raised capital through a $30 million private placement to support its development programs. Financial disclosures indicate a net loss and substantial liquidity as of the latest quarter.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ImageneBio, Inc. is a biopharmaceutical company formed through the merger of Ikena Oncology and Inmagene Biopharmaceuticals. The company is focused on advancing its drug candidate IMG-007. Recent developments include leadership appointment, a reverse stock split, shareholder support for merger-related share issuance, and a $30 million private placement to fund development. The latest SEC filing as of September 30, 2026, shows a net loss and strong liquidity ratios.
The company has secured significant financing through a $30 million private placement to advance IMG-007, indicating investor interest and resource availability for development [N1]. The merger consolidates expertise and assets from two biopharmaceutical entities, potentially enhancing operational capabilities and pipeline strength [N7][N8]. Leadership under CEO Kristin Yarema, Ph.D., may provide strategic direction and execution focus [N3]. Strong liquidity ratios as of September 2026 provide financial flexibility to support ongoing research and development [S2].
ImageneBio reported a net loss of $15.62 million for the quarter ending September 30, 2026, reflecting ongoing expenses without current profitability [S2]. The company operates in a high-risk biopharmaceutical sector where clinical and regulatory outcomes can be uncertain. The need for continuous capital raises, such as the recent private placement, underscores the cash burn and dependency on external funding [N1]. The merger and restructuring activities may present integration and execution risks.
ImageneBio's moat is primarily based on its proprietary drug candidate IMG-007 and the strategic merger that combined resources and expertise from Ikena Oncology and Inmagene Biopharmaceuticals. The support from ISS and Glass Lewis for the merger-related share issuance suggests institutional confidence in the company's strategic direction. The company's liquidity position provides a buffer to fund ongoing development activities, which is critical in the biopharmaceutical industry where product development cycles are long and capital intensive.
• Clinical and Regulatory Risk: The success of IMG-007 depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain and can impact the company's future operations.
• Financial Risk: The company reported net losses and relies on external financing, such as private placements, to fund development activities, which may dilute existing shareholders and affect financial stability.
• Integration Risk: The merger between Ikena Oncology and Inmagene Biopharmaceuticals requires effective integration of operations, personnel, and strategy to realize potential benefits.
Business trends: The company is focused on advancing its drug candidate IMG-007 through merger consolidation and capital raising efforts.
Execution milestones: Completion of merger, leadership appointment, reverse stock split, shareholder approvals, and private placement financing.
Key risks: Clinical and regulatory uncertainties, financial sustainability due to ongoing losses, and integration challenges post-merger.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- ImageneBio, Inc. is the result of a merger between Ikena Oncology and Inmagene Biopharmaceuticals, trading under ticker IMA on Nasdaq.
- Kristin Yarema, Ph.D., was appointed CEO of ImageneBio following the merger [N3].
- The company completed a 1-for-12 reverse stock split concurrent with the merger announcement [N4].
- ISS and Glass Lewis supported the share issuance related to the merger, indicating shareholder approval processes were underway and supported [N5][N6].
- A definitive merger agreement was announced on December 23, 2024, to advance development of the drug candidate IMG-007 [N7][N8].
- ImageneBio conducted a $30 million private placement to advance development of IMG-007 [N1].
- The company reported a net loss of $15.62 million for the quarter ending September 30, 2026, with basic and diluted EPS of -$0.91 per share [S2].
- As of September 30, 2026, the company held $84.85 million in cash and equivalents and $41.74 million in short-term investments, with a current ratio of 16.17 and a cash ratio of 15.68, indicating strong liquidity [S2].
- Trading of Ikena Oncology resumed on December 23, 2024, coinciding with merger activities [N7].
- The company announced strategic restructuring and exploration options in May 2024 [N14].
Generated 2026-11-11
- S1 | 2026-03-10 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-04-13 | www.nasdaq.com | ImageneBio Unveils $30 Mln Private Placement To Advance IMG-007 ;Stock Up | https://www.nasdaq.com/articles/imagenebio-unveils-30-mln-private-placement-advance-img-007-stock
- N2 | 2025-08-05 | www.nasdaq.com | Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade | https://www.nasdaq.com/articles/wall-street-analysts-believe-imagenebio-inc-ima-could-rally-69548-heres-how-trade
- N3 | 2025-07-23 | www.nasdaq.com | Ikena Oncology and Inmagene Biopharmaceuticals Announce Appointment of Kristin Yarema, Ph.D. as CEO of ImageneBio Following Merger | https://www.nasdaq.com/articles/ikena-oncology-and-inmagene-biopharmaceuticals-announce-appointment-kristin-yarema-phd-ceo
- N4 | 2025-07-15 | www.nasdaq.com | Ikena Oncology Announces 1-for-12 Reverse Stock Split and Merger with Inmagene Biopharmaceuticals, to Trade as ImageneBio, Inc. on Nasdaq Under Ticker "IMA" | https://www.nasdaq.com/articles/ikena-oncology-announces-1-12-reverse-stock-split-and-merger-inmagene-biopharmaceuticals
- N5 | 2025-07-11 | www.nasdaq.com | ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger | https://www.nasdaq.com/articles/iss-and-glass-lewis-support-ikenas-share-issuance-proposed-inmagene-merger
- N6 | 2025-07-11 | www.nasdaq.com | Ikena Oncology Announces Support from ISS and Glass Lewis for Shareholder Vote on Inmagene Merger | https://www.nasdaq.com/articles/ikena-oncology-announces-support-iss-and-glass-lewis-shareholder-vote-inmagene-merger
- N7 | 2024-12-23 | www.nasdaq.com | Ikena Oncology and Inmagene Biopharmaceuticals Announce Definitive Merger Agreement to Advance Development of IMG-007 | https://www.nasdaq.com/articles/ikena-oncology-and-inmagene-biopharmaceuticals-announce-definitive-merger-agreement
- N8 | 2024-12-23 | www.nasdaq.com | iKena Oncology, Inmagene enter definitive merger agreement, private placement | https://www.nasdaq.com/articles/ikena-oncology-inmagene-enter-definitive-merger-agreement-private-placement
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


